Drug Type Monoclonal antibody |
Synonyms lendalizumab, Lendalizumab (USAN), Olendalizumab (USAN) + [1] |
Target |
Mechanism C5a inhibitors(complement C5a inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Graft Versus Host Disease | Phase 2 | US | 14 Nov 2014 | |
Acute Graft Versus Host Disease | Phase 2 | FR | 14 Nov 2014 | |
Graft versus host disease in gastrointestinal tract | Phase 2 | US | 14 Nov 2014 | |
Graft versus host disease in gastrointestinal tract | Phase 2 | FR | 14 Nov 2014 | |
Antiphospholipid Syndrome | Phase 2 | US | 01 Apr 2014 | |
Antiphospholipid Syndrome | Phase 2 | JP | 01 Apr 2014 | |
Antiphospholipid Syndrome | Phase 2 | BR | 01 Apr 2014 | |
Antiphospholipid Syndrome | Phase 2 | FR | 01 Apr 2014 | |
Antiphospholipid Syndrome | Phase 2 | IT | 01 Apr 2014 | |
Antiphospholipid Syndrome | Phase 2 | GB | 01 Apr 2014 |
Phase 2 | 25 | (ALXN1007 10 mg/kg Once Weekly) | olkcqdcyjp(vygvczrpnk) = kwdlowpfwd kjfjxobsps (xvxurtpjbx, pquokgpsbn - aoyetucbei) View more | - | 06 Oct 2017 | ||
(ALXN1007 20 mg/kg Once Weekly) | olkcqdcyjp(vygvczrpnk) = gfznxdbqnv kjfjxobsps (xvxurtpjbx, ceelhakufd - ivzukzkwsi) View more | ||||||
Phase 2 | 9 | pvckavgwpb(rdaymfilab) = jxckdetbgl mdbmoiggxy (jffzkygvao, whwbuecqxb - ozslhfttgb) View more | - | 13 Jul 2017 |